Biotechnology News and Research

RSS

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems, a leader in preclinical contract testing of drugs, biologics, and medical devices, announces that it has been subcontracted by the German pharmaceutical company Merck KGaA to work on a new pediatric formulation of praziquantel.

7 Oct 2014

Cognizant announces acquisition of Cadient Group

Cognizant today announced it has acquired Cadient Group, a full-service digital marketing agency that serves a broad spectrum of life sciences companies in the pharmaceutical, biotechnology, consumer health, and medical device industries.

7 Oct 2014

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).

7 Oct 2014

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences.

6 Oct 2014

New method for extracting potential bone-producing cells from human fat

Within our fat lives a variety of cells with the potential to become bone, cartilage, or more fat if properly prompted. This makes adipose tissue, in theory, a readily available reservoir for regenerative therapies such as bone healing if doctors can get enough of those cells and compel them to produce bone.

6 Oct 2014

TxCell to highlight development, progress of ASTrIA platform at 13th Annual BIO Investor Forum

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.

3 Oct 2014

Novel test could revolutionise discovery of new prescription drugs

A new test developed by researchers from the University of Manchester could revolutionise the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available.

From The University of Manchester 3 Oct 2014

BioCap conference showcased life sciences companies in the North

The unique BioCap conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry, was a great success, combining the forces of science and financial investment enabling businesses from all over the North to secure essential funding.

3 Oct 2014

Women survivors of sexual abuse may suffer emotional distress during pelvic examination

Women who have a history of violent sexual abuse may suffer emotional distress during a routine pelvic examination. Healthcare providers would benefit from greater awareness of symptoms predictive of examination-related distress in this patient population, according to a study published in Violence and Gender, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

3 Oct 2014

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease.

3 Oct 2014

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history.

1 Oct 2014

Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay.

1 Oct 2014

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera Sciences, Inc. (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules).

1 Oct 2014

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

DanDrit Biotech A/S ("DanDrit Denmark"), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa.

30 Sep 2014

Allakos secures additional $10M investment to expand its development portfolio

Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody.

30 Sep 2014

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

30 Sep 2014

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae.

From Luminex 30 Sep 2014

ChromaDex closes $5.0 million growth capital debt financing

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it closed on a $5.0 million growth capital debt financing from Hercules Technology Growth Capital.

30 Sep 2014

Three institutions collaborate to study genetics of bipolar disorder, schizophrenia

Researchers at the University of Michigan School of Public Health and Medical School and collaborators at two other institutions will undertake the largest whole genome sequencing study funded to date, as they seek to better understand bipolar disorder and schizophrenia.

30 Sep 2014

Baxter to establish new innovation and R&D center in Cambridge, MA

BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new lease for approximately 200,000 square feet for 12 years with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., at 650 East Kendall Street in Cambridge, Massachusetts, which is owned by BioMed Realty through a joint venture with Prudential Real Estate Investors.

From Baxter International Inc. 30 Sep 2014